J Rheum Dis 2019; 26(4): 278-281  
A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
Sang Jin Lee1, Han-Ki Park2, Yong-Sun Kim3
1Division of Rheumatology, Department of Internal Medicine, 2Division of Allergy and Clinical Immunology, Department of Internal Medicine, and 3Department of Neuroradiology, School of Medicine, Kyungpook National University, Daegu, Korea
Correspondence to: Sang Jin Lee http://orcid.org/0000-0002-7892-6482
Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. E-mail : dream1331@naver.com
Received: July 2, 2019; Revised: August 16, 2019; Accepted: August 21, 2019; Published online: October 1, 2019.
© Korean College of Rheumatology. All rights reserved.

This is a open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
Keywords: Ankylosing spondylitis, Interleukin 17A, Neurosyphilis

This Article